Fujirebio Holdings, Inc. (Headquarters: Minato-ku, Tokyo; President & CEO: Goki Ishikawa) and Sysmex Corporation (Headquarters: Kobe, Japan; President: Kaoru Asano) jointly announce a Basic Agreement on Business Collaboration to foster a multifaceted partnership encompassing research and development, production, clinical development, and sales-marketing in the field of immunoassay.

With over 50 years of involvement in the in vitro diagnostics sector, Sysmex has established a robust technological base and a global network. To fortify its diagnostics business, the company aims to expedite the expansion of its immunochemistry business in worldwide markets, including the United States and Europe. In recent years, Sysmex has focused on developing and offering unique tests that generate novel value, such as introducing reagents for the detection of amyloid beta (Aβ) accumulation in the brain, a key contributor to Alzheimer's disease, from blood samples in the Japanese and US LDT1 markets.

Fujirebio possesses an extensive range of reagent raw materials and product portfolios derived from its long-standing involvement in immunoassay. In recent years, in addition to advancing its own product offerings, Fujirebio has strengthened its Contract Development and Manufacturing Organization (CDMO) strategy to advance the global development of distinctive tests. As part of this initiative, since 2020, Fujirebio, via its subsidiaries, has been developing specialized reagents for Sysmex's Automated Immunoassay System HISCL™-Series.

Both companies have reached an agreement to intensify their collaboration, grounded in the shared conviction that combining their respective expertise and immunoassay capabilities will expedite their global expansion and contribute to the evolution and progress of immunoassay. Their future plans include selecting specific areas for collaboration from a wide array of possibilities, including research and development, production, clinical development, and sales-marketing, with the goal of commencing execution by the end of March 2024.

Fujirebio and Sysmex are committed to delivering high-value testing to clients worldwide at the earliest opportunity through the reinforced partnership in immunoassay.

 

 

Report Abuse